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Objectives: Blood pressure control is important after repair of coarctation of the
aorta. We report the first prospective multi-institutional trial addressing the safety
and efficacy of esmolol after repair of coarctation of the aorta in infants and
children.
Methods: The primary objective of this phase IIIb, multicenter, double-blind, random-
ized, dose-ranging trial was the efficacy of esmolol to control hypertension. Candi-
dates included subjects younger than 6 years and weighing 2.5 kg or more who
underwent surgical intervention for coarctation of the aorta and required therapy
for systemic hypertension. One hundred sixteen subjects received esmolol: 36
received a low dose (125 mg/kg), 43 received a medium dose (250 mg/kg), and 37
received a high dose (500 mg/kg). The primary outcomes were the change in systolic
blood pressure and the need for additional antihypertensive rescue medication 5 min-
utes after the initiation of esmolol.
Results:All dose groups showed a significant decrease from baseline in systolic blood
pressure (29.66 16.3 mmHg, P, .001). There were no differences in systolic blood
pressure response at 5 minutes between dose groups (high, medium, or low) or age
groups. The need for rescue medication at 5 minutes was not different between
dose groups. All dose groups showed similar incidences of adverse events. There
were no serious adverse events.
Discussion: Esmolol can be administered safely to patients younger than 6 years after
repair of coarctation of the aorta. In the dose range of 125 to 500 mg/kg, esmolol
significantly decreased systolic blood pressure.
C
oarctation of the aorta (CoA) comprises approximately 6% of all congen-
ital heart disease.1 The surgical mortality of isolated coarctation is low at
0.5% to 2.5%.2,3 Hypertension occurs in more than 65% of subjects during
the postoperative period after surgical CoA repair.4-6 The short-acting and selec-
tive b1-antagonist esmolol hydrochloride (esmolol) has been shown to achieve
early and predictable steady-state blood levels and to have a short duration of ac-
tion.7,8 Esmolol has been shown to control hypertension in children after cardiac
surgery9 and specifically after CoA repair (in both case reports10 and small se-
ries9,11). This article is the first multicenter report of the dose response and safety
of esmolol for the treatment of hypertension in infants and children after CoA re-
pair. The primary aim was 2-fold: (1) the change in blood pressure from baseline
and (2) the need for antihypertensive rescue medications. The secondary aims
were (1) dose dependence, (2) age dependence, (3) pharmacokinetics, and (4)
safety assessment.
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DAbbreviations and Acronyms
AE 5 adverse event
ANOVA 5 analysis of variance
CoA 5 coarctation of the aorta
FDA 5 US Food and Drug Administration
SBP 5 systolic blood pressure
Materials and Methods
This phase IIIb, multicenter, double-blind, randomized, active con-
trol, dose-ranging study was conducted at 20 institutions in North
America; the institutional review board at each site approved the
study. This study (protocol no. 20,015-004 entitled ‘‘A multi-center
study to evaluate the efficacy, safety and pharmacokinetics of esmo-
lol hydrochloride (Brevibloc) for treatment of hypertension in in-
fants and children after surgical repair of coarctation of the
aorta’’) was approved by the US Food and Drug Administration’s
(FDA) Division of Cardio-Renal Drug Products and monitored by
the FDA’s Bioresearch Monitoring Program. The steering commit-
tee, composed of cardiac anesthesiologists and cardiac intensivists
from 3 high-volume pediatric centers (Children’s Hospital of Phila-
delphia, Boston Children’s Hospital, and Cleveland Clinic), assisted
in the study design to ensure consistency with standard of care. Pe-
diatric patients younger than 6 years and weighing 2.5 kg or more
scheduled for surgical repair of CoA through a lateral thoracotomy
were screened for eligibility. Participation in the study required a 2-
stage eligibility process. Patients were evaluated in the preoperative
phase to determine whether they were eligible for enrollment. Pa-
tients meeting screening criteria and for whom informed consent
was obtained were randomized before surgical intervention. The fi-
nal inclusion criteria were determined based on systolic blood pres-
sure (SBP) after aortic crossclamp release.
Preliminary exclusion criteria included any of the following: (1)
an awake resting heart rate of less than 120 beats/min for a neonate
(#28 days), less than 90 beats/min for an infant (.28 days to ,1
year), or less than 70 beats/min for a child ($1 year to 6 years);
(2) reactive airway disease that required any form of therapy within
the previous week or required hospital admission within the past
year; (3) a known sensitivity to b-blockers; (4) hypoglycemic pre-
sentation at the time of screening evaluation; (5) participation in
a randomized study or exposure to any experimental drug within
28 days before enrollment; (6) concomitant complex congenital
heart disease requiring cardiopulmonary bypass; (7) shock, acidosis,
and/or decreased left ventricular function within 48 hours of surgical
intervention; (8) abnormal clinical laboratory values; (9) previous
treatment in the study; or (10) on-going treatment with a b-blocker
or long-acting antihypertensive agent. Final inclusion criteria were
hypertension that required treatment (neonate, SBP$80mmHg; in-
fant, SBP$85 mm Hg; child, SBP$95 mm Hg) within 30 minutes
of crossclamp release and no prior intraoperative antihypertensive
treatment, with the exception of nitroprusside, before crossclamp re-
lease. Nitroprusside use was permitted during surgical intervention
provided it was stopped at least 2 minutes before crossclamp release
and at least 10 minutes before the time the study drug was to be ad-
ministered. The subject must also have not received any inotropic
agent for the treatment of hypotension after crossclamp release.322 The Journal of Thoracic and Cardiovascular Surgery c AuInterventions
The steering committee determined that a placebo-controlled design
was not feasible because of the need to rapidly control blood pres-
sure in this subject population, and thus a dose-ranging design
was used. The dose range was determined by the steering committee
to span the standard of care. Subjects were randomly assigned to re-
ceive a low dose (125 mg/kg), medium dose (250 mg/kg), or high dose
(500 mg/kg). An initial bolus dose of either 125, 200, or 500 mg/kg
was administered over 10 to 20 seconds into a free-running desig-
nated intravenous line, followed by continuous infusion, at the
same minutely rate, maintained at a rate of 1.5 mL $ kg21 $ h21
for at least 15 minutes to complete the primary efficacy assessments
and sampling for pharmacokinetic analysis. Rescue medication was
permitted 5 minutes after the loading dose if the subject’s SBP had
not decreased to less than the threshold for study drug administra-
tion. The choice and dose of antihypertensive rescue medication
was at the discretion of the anesthesiologist and surgeon. After the
15-minute dose-response phase was completed, blood pressure
management could be accomplished by (1) increasing or decreasing
the blinded esmolol administration rate, (2) adding unblinded esmo-
lol to the blinded esmolol infusion, or (3) adding any additional
antihypertensive treatments the investigator deemed appropriate.
Blinded esmolol administration was permitted for up to 12 hours,
after which open-label esmolol could be continued at the discretion
of the investigator.
Objectives/Outcomes
The primary end points were (1) change in SBP and (2) the percent-
age of subjects requiring rescue medication 5 minutes after the initi-
ation of esmolol. Efficacy parameters included the change in SBP at
5 minutes when comparing age groups and dose groups. Heart rate
and blood pressure during anesthesia were measured with a right up-
per extremity arterial catheter. Blood pressures were measured with
an arterial catheter until the catheter was removed, after which non-
invasive automated blood pressures were obtained. Heart rate and
blood pressure were measured immediately before administration
of the study drug loading dose and at 1-minute intervals until 15min-
utes after the loading dose. The secondary objective was to deter-
mine the pharmacokinetics of esmolol when administered as an
infusion after a loading dose and to asses the tolerability and safety
of esmolol infusion in infants and children after repair of CoA.
Randomization
Acentrally administered, balanced, computerized, dynamic random-
ization scheme was used for the randomization of subjects to dose
groups. Subjects who were randomized but who did not become hy-
pertensive within the protocol-specified timeframe were considered
screen failures. Randomized subjects who did not receive study drug
orwere not evaluable for efficacywere replaced through the dynamic
randomization scheme. The system verified that the difference be-
tween any 2 treatment groups never varied by more than 2 subjects.
Clinicians and clinical research personnel, including medical
monitors, site monitors, and statisticians, were kept blinded to the
dose of study drug until the conclusion of the study.
Data Quality Assurance
Sponsor clinical research associates performed initiation and routine
monitoring visits to all 20 sites. Data from case report forms weregust 2008
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ward, Inc, Waltham, Mass). Data queries were returned by clinical
research associates and resolved by individual sites.
Safety Reporting and Adverse Events
Adverse events (AEs) were collected and rated by severity and rela-
tionship to study drug by the investigators. AEs were summarized
overall and by sex, race, age group, and concealed dose groups.
These data were made available to the Date Safety Monitoring
Board and individual institutional review boards. Two interim anal-
yses of AE data were performed after 30 and 60 patients were
enrolled. Investigational New Drug (IND) Safety Reports were
sent to the FDA and to all individual institutional review boards.
Statistical Methods
Data analyses were performed by Baxter Healthcare Corporation
(Deerfield, Ill) in conjunction with statisticians at the Children’s
Hospital of Philadelphia (XZ). SAS Version 8.1 for Windows
(SAS, Inc, Cary, NC) was the primary statistical software used.
All statistical tests, except the primary end points, were based on
a 2-tailed test at a .05 significance level. There were 5 subsets of
data analyzed for this study: (1) all patients who randomized, re-
gardless of treatment with esmolol; (2) safety, randomized patients
who received any esmolol; (3) intent-to-treat efficacy, randomized
patients who received esmolol and had a blood pressure measure-
ment at 5 minutes after loading dose or earlier if hypotensive; (4)
per-protocol efficacy, patients in intent-to-treat efficacy who did
not have major protocol violations; and (5) pharmacokinetics, ran-
domized patients who received esmolol and had valid drug concen-
tration data. The intent-to-treat and per-protocol populations were
used in the efficacy analysis.
There were 2 primary efficacy outcome measures: (1) the change
in SBP and (2) the need for rescue medication. For the primary ef-
ficacy outcome, the change from baseline in SBP measured before
the esmolol loading dose and at 5 minutes after the loading dose
and the differences in the 3 dose groups were compared by using
a 1-way analysis of variance (ANOVA), with the dose groups as
the factor levels. Tukey pairwise comparisons were performed
when statistical significance was found to establish which dose
groups had similar or different effects. The primary efficacy out-
come of the percentage of patients requiring rescue medication
within 5 minutes after starting the esmolol infusion was determined
by using 2 methods. The first analysis was a 1-sided Cochran–Ar-
mitage linear trend test with the null hypothesis that the percentage
of patients requiring rescue medication was comparable across all 3
dose groups. The second analysis hypothesized that there was an or-
der between the percentage of patients requiring medication and the
decrease in percentage of rescue medication with increased dose.
This was evaluated by using an exact c2 test comparing the percent-
ages of patients requiring rescue medication.
The secondary efficacy parameter used a 2-way ANOVA analy-
sis for change in SBP at 5 minutes, with age groups being the
secondary factor to account for the different blood pressure thresh-
olds for entry and exclusion from the study for each age group.
Additional outcome measures of diastolic blood pressure, mean ar-
terial pressure, and heart rate were investigated. One-way ANOVA
for change from baseline at 5 minutes was used, with the dose
groups as the factor levels.The Journal of ThorFor safety analysis, AEs were summarized as the percentage of
patients with any AE and by each specific AE and system organ
class overall and by dose group.
Pharmacokinetics–pharmacodynamics
Blood samples of 1 to 1.5 mLwere taken from the arterial line before
the loading dose was given and at 5, 10, and 15 minutes after the
loading dose. All blood samples were processed, stored, and shipped
to the reference laboratory (Division of Clinical Pharmacology and
Therapeutics at The Children’s Hospital of Philadelphia) and ana-
lyzed for plasma esmolol concentration by using a previously pub-
lished method.12 Because a sparse sampling was used for the study,
pharmacokinetic analyses were performed by using data from the
population. Patients with documented problems or errors in drug
administration were excluded from pharmacokinetic analyses.
Clearance was calculated by dividing the infusion rate by the
steady-state concentration. The half-life of accumulation was deter-
mined by dividing 0.693 by the rate constant. A regression analysis
of steady-state concentration (Css) versus infusion rate was per-
formed to define whether the pharmacokinetics of esmolol over
the patient age range were linear.
Protocol Amendment
There was one protocol amendment made during this study. The
analysis planwasmodified and the sample sizewas increasedper a re-
quest from the FDA.The protocolwas revised to perform the primary
efficacy analyses by using the assumption that the 2 primary end
points were correlated and to perform the analysis of the percentage
of subjects requiring rescue medication as a 2-tailed test. This revi-
sion resulted in an increased sample size of 20%, from 90 efficacy-
evaluable subjects (with 120 randomized to account for dropouts).
Results
Eligible participants were recruited from August 2000 until
November 2002. Subjects were screened preoperatively
and participated in the study from the time of induction of an-
esthesia until hospital discharge. One hundred sixty-four sub-
jects consented to participate in the study (Figure 1). Of the
subjects randomized, 118 met the final inclusion criteria for
study participation and received esmolol, 36 in the low-
dose (125 mg/kg), 44 in the medium-dose (250 mg/kg), and
38 in the high-dose (500 mg/kg) groups. Of the 118 subjects
treated with esmolol, 116 were included in the intent-to-treat
subset as the primary end point (blood pressure at 5 minutes
could not be measured for 2 subjects). One hundred ten sub-
jects were included in the per-protocol efficacy subset be-
cause 6 subjects had protocol violations: incorrect loading
dose (n5 2), incorrect infusion rate (n5 2), delay in contin-
uous infusion (n5 1), and nipride administered before 5 min-
utes after blinded study drug administration (n 5 1). All
other deviations did not adversely affect the ability to inter-
pret the study efficacy or safety data and were considered
minor. Blood samples for pharmacokinetic analysis were
available for 117 subjects; 107 were interpretable. The safety
subset was used for safety analysis and included all 118 sub-
jects who were treated with any esmolol.acic and Cardiovascular Surgery c Volume 136, Number 2 323
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groups with respect to their medication history, prestudy
physical examination findings, or medical history abnormal-
ities (Table 1).
Primary Outcomes
There was a significant decrease in SBP at 5 minutes in all
dose groups compared with baseline values (Table 2). No
statistical difference was found between dose groups. There
was no difference between dose groups in the change (P 5
.24) from baseline in SBP. In the intent-to-treat subset, 63
Figure 1. Flow diagram of patients in whom informed consent was
obtained and randomization occurred. BP, Blood pressure.(54%) of the subjects met the criteria for rescue medication
after 5 minutes of blinded esmolol. Two analyses were per-
formed on these data: an exact c2 test to verify that the
proportions of patients who met the criteria for and who
were given rescue medications were the same and a Co-
chran–Armitage linear trend test to determine whether
a trend existed across the dose groups. There were no sta-
tistical differences found (Table 2). Thirty-nine (62%) of
the patients who met the criteria actually received rescue
medication at 5 minutes after the start of esmolol. The
types of rescue medications included increased isoflurane,
nitroprusside, fentanyl, and propofol. Some patients
received more than 1 agent.
Secondary Outcomes
There was no statistical difference in SBP response between
age groups (neonate, infant, and child; P 5 .32). There were
no statistical differences between dose groups for change
from baseline in diastolic blood pressure or mean arterial
pressure at 5 minutes after esmolol administration. There
was a statistical difference seen in change from baseline
in mean heart rate 5 minutes after esmolol administration
for the per-protocol efficacy analyses and a trend toward
significance in the intent-to-treat analyses (Table 3). There
was no relationship between percentage decrease in SBP
at 5 minutes and the simultaneous arterial plasma esmolol
concentration. Subjects’ heart rate decreased at 5 minutes
with increasing arterial plasma esmolol concentration (r 5
0.41).
Esmolol was discontinued when it was no longer believed
to be needed because of hemodynamic stability (n 5 75
[68%]), inadequate blood pressure control (n 5 6 [6%]),
AEs (n 5 7 [6%]), or ‘‘other’’ (n 5 22 [20%]).TABLE 1. Demographics*
Low dose Medium dose High dose Overall
N 36 44 38 118
Age (mo)
Mean (SD) 18.7 6 23.0 19.4 6 24.5 14.6 6 19.4 17.6 6 22.4
Sex (n)
Male/female 21/15 32/12 26/12 79/39
Race (n [%])
White 26 (72%) 33 (75%) 25 (66%) 84 (71%)
Hispanic 5 (14%) 9 (20%) 11 (29%) 25 (21%)
Black 3 (8%) 2 (5%) 2 (5%) 7 (6%)
Other/unknown 2 (6%) 0 (0%) 0 (0%) 2 (2%)
Weight (kg)
Mean (SD) 9.3 6 6.5 9.5 6 6.2 8.4 6 5.5 9.1 6 6.0
Age group (n [%])
#28 days 9 (25%) 12 (27%) 5 (13%) 26 (22%)
.28 d to ,1 y 14 (39%) 13 (30%) 18 (47%) 45 (38%)
$1 y to 6 y 13 (36%) 19 (43%) 15 (39%) 47 (40%)
SD, Standard deviation. *Safety dataset: all patients receiving study esmolol.
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A total of 107 patients had pharmacokinetic data further
analyzed: 22 newborns, 42 infants, and 43 children. The
15-minute arterial plasma esmolol concentration was signif-
icantly higher in children compared with that seen in new-
borns (P , .0001) and infants (P 5 .001); no difference
was detected between newborns and infants. Plasma esmolol
concentrations appeared to increase in proportion to dose
(Figure 2). The time to steady state did not differ significantly
as a function of age, and patients were approaching steady
state by 15 minutes.
The elimination rate constant (6 standard error) deter-
mined across dose levels was 0.146 6 0.04 (r2 5 0.67).
The time to steady state for the population was 21 minutes,
with a half-life of accumulation (equivalent to the half-life
of elimination for a drug administered by means of continu-
ous intravenous infusion) of 4.8 minutes. For children, the
CSS values (6 standard error) for the 125, 250, and 500
mg/kg dose levels were 992 6 143, 1983 6 287, and 3967
6 573 ng/mL, and for the newborn/infants, the CSS values
(6 standard error) for the 125, 250 and 500 mg $ kg21 $
min21 dose levels were 444 6 60, 888 6 120, and 1777 6
240 ng/mL, respectively.
Esmolol clearance was greater in the newborn/infant
group (281 mL $ kg21 $ min21; 95% confidence limit
[CL], 267–296 mL $ kg21 $ min21) compared with that for
children (126 mL $ kg21 $ min21; 95% CL, 83–169 mL $
kg21 $ min21). Because of the high degree of interpatient
variability, individual drug clearances could not be calcu-
lated, and thus correlation between age and clearance could
not be performed.
Adverse Events
There were no deaths and no serious AEs. Most of the com-
plications were typical of patients recovering from surgical
CoA repair. All 3 dose groups showed similar incidences
of AEs. The most frequent AEs were postoperative pain
(n 5 90 [76%]), postoperative agitation (n 5 24 [20%]),
postoperative anemia (n 5 22 [19%]), hypokalemia (n 5
32 [27%]), and metabolic acidosis (n 5 33 [28%]; Table 4).
Specific to this patient population were bleeding that required
transfusion (n 5 35 [30%]), pneumothorax (n 5 17 [14%]),
and sequelae associated with the esmolol intravenous infu-
sion site (n 5 1 [1%]).
There were 17 AEs that are known therapeutic end points
or previously described side effects of esmolol: hypotension
TABLE 2. Primary end point evaluation (intent-to-treat subset)
Parameter Statistic/category Low dose Medium dose High dose Overall P value
Change from baseline in systolic blood pressure within 5 min after esmolol start
N 36 43 37 116
Change from baseline (mm Hg) Mean (SD) 26.0 6 12.6 212.2 6 16.8 210.2 6 18.7 29.6 6 16.3 .24
Tests for change from baseline equal to 0 T (P value) 22.9 (,.01) 24.8 (,.001) 23.3 (,.01) 26.3 (,.001)
Rescue medication at 5 min after blinded esmolol start
Met rescue criterion 22 (61%) 21 (49%) 20 (54%) 63 (54%) .54y
.56z
Rescue medication at 5 min* 12 (33%) 12 (28%) 15 (41%) 39 (34%) .48y
.54z
Type of rescue medication;
Increased isoflurane 9 (75%) 12 (100%) 13 (87%) 34 (87%)
Nitroprusside 3 (25%) 1 (8%) 1 (7%) 5 (13%)
Fentanyl 0 (0%) 1 (8%) 1 (7%) 2 (5%)
Propofol 1 (8%) 0 (0%) 0 (0%) 1 (3%)
SD, Standard deviation. *Subjects might have received more than 1 rescue medication. yExact c2 test. zCochran–Armitage linear trend test.
TABLE 3. Change from baseline in heart rate at 5 minutes after the start of esmolol
Parameter Statistic/category Low dose Medium dose High dose P value
Per-protocol N 33 41 35
Change from baseline (beats/min) Mean (SD) 26.8 6 9.9 214.2 6 8.5 213.2 6 12.7 .007
95% CL 210.4 to 23.3 217.4 to 211.0 216.7 to 29.7
Intent to treat N 36 31 75
Change from baseline (beats/min) Mean (SD) 27.4 6 9.7 213.2 6 10.7 212.3 6 12.9 .06
95% CL 211.1 to 23.7 216.6 to 29.8 215.3 to 28.6
SD, Standard deviation; CL, confidence limit.
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[3%]), and reaction at the injection site (n 5 1 [1%]). Seven
subjects discontinued the study because of AEs: hypotension
(n5 5), bilateral wheezing (n5 1), and reaction at the injec-
tion site (n 5 1).
Discussion
CoA can present critically in infancy when the ductus arterio-
sus closes or later during childhood. The current approach to
isolated CoA is either surgical, usually through a thoracot-
omy,2,3 or through interventional catheterization with a bal-
loon angioplasty or intravascular stent.13,14
Hypertension occurs in more than 65% of subjects during
the postoperative period after surgical coarctation repair.4-6
Theories about the cause of postoperative hypertension
include activation of the sympathetic nervous system, the
renin–angiotension system, or both. More recent studies im-
plicate abnormalities in the elastic properties of the aorta15
and autonomic dysfunction16 as causes for postoperative
hypertension, particularly in newborns.
The use of b-blockade (propranolol) in children during the
perioperative period for coarctation repair has been shown to
result in a significant decrease in SBP and diastolic blood
pressure and in plasma renin activity.6 Esmolol has several
advantages over propranolol: rapid hydrolysis by red blood
Figure 2. Concentration time curves for the 125 (circles), 250
(squares), and 500 (triangles) mg $ kg21 $ min21 dose levels.
The child age group is shown with dotted lines and gray symbols,
and the newborn/infant groups are shown with solid lines and
black symbols. Mean 6 standard deviation arterial plasma
concentrations are shown. Curve fits were derived by using all
concentration time point data and not the mean values.326 The Journal of Thoracic and Cardiovascular Surgery c Aucell esterases17 and selective, competitive b1-blockade.
7 Ini-
tial pharmacokinetic data examining the use of esmolol in
children indicate a faster elimination than reported in
adults.8,9,18 Esmolol has been shown to control hypertension
in children after cardiac surgery9 and specifically after CoA
repair (in both case reports10 and small series9,11). When
used as a single antihypertensive agent, reports indicate
that higher doses might be required after CoA repair (830
6 153 mg $ kg21 $ min21) compared with other lesions10
and higher doses than suggested in the product label (300
mg $ kg21 $ min21).
This article reports the first dose-response and safety study
of esmolol for the treatment of hypertension in infants and
children after CoA repair. The primary aim was to determine
the efficacy (n5 116) at 3 dose levels of controlling postop-
erative hypertension within 30 minutes of aortic crossclamp
release and at 5 minutes after the initiation of esmolol. The
secondary aims were (1) the pharmacokinetics (n 5 107) of
esmolol when administered as a bolus followed by an imme-
diate infusion and (2) the safety (n 5 118) of esmolol use in
this population.
We found a significant decrease in SBP at 5 minutes after
initiation of esmolol compared with baseline values in all
dose groups, with no significant difference between dose
groups. When patients were divided into age groups, there
was still no significant difference in the effect on SBP be-
tween dose groups. The chosen dosing range (125–500 mg
$ kg21 $ min21) was considered by the advisory committee
to be within the standard of care. A placebo control was
not believed to provide clinical equipoise. Other studies
have suggested that higher doses of esmolol might be neces-
sary when used as a single antihypertensive agent.10 Al-
though some patients received higher doses of esmolol
(either blinded or open label), it occurred outside the close
blood pressure monitoring window of the study and in con-
junction with other antihypertensive agents. Thus the effect
of higher-dose esmolol could not be evaluated in this study
population. It might also be that esmolol in this range is
most effective if used in combination with an antihyperten-
sive agent with an alternative mode of action, such as
nitroprusside. Finally, it is possible that the incremental
difference between dose ranges was too small to result in
a statistically significant difference in blood pressure. This
is supported by the pharmacokinetic finding of significant
interpatient variability within each dose group.
Plasma esmolol concentration increased in proportion to
dose over the 125 to 500 mg $ kg21 $ min21 dose range. In
addition, there was a 4-fold increase in 5-, 10-, and 15-minute
plasma drug concentrations, respectively. Although there
was significant interpatient variability, the esmolol clearance
in children of 126 mL $ kg21 $ min21 was similar to that
reported in other recent pediatric studies,8,9,19 whereas clear-
ance in newborns (281 mL $ kg21 $min21) was considerably
greater.gust 2008
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System organ class/adverse event Low dose (n 5 36) Medium dose (n 5 44) High dose (n 5 38) Overall (n 5 118)
Cardiac disorders
Tachycardia NOS 3 (8) 5 (11) 3 (8) 11 (9)
Gastrointestinal disorders
Constipation 3 (8) 2 (5) 10 (26) 15 (13)
General disorders
Pyrexia 3 (8) 8 (18) 4 (11) 15 (13)
Injury, poisoning, and procedural complications
Agitation postoperative 6 (17) 10 (23) 8 (21) 24 (20)
Anemia postoperative 6 (17) 8 (18) 8 (21) 22 (19)
Pain postoperative 27 (75) 35 (80) 28 (74) 90 (76)
Vomiting postoperative 3 (8) 4 (9) 5 (13) 12 (10)
Metabolism and nutritional disorders
Hypocalcemia 3 (8) 6 (14) 3 (8) 12 (10)
Fluid overload 2 (6) 2 (5) 6 (16) 10 (8)
Hypokalemia 10 (28) 10 (23) 12 (32) 32 (27)
Metabolic acidosis 9 (25) 12 (27) 12 (32) 33 (28)
Renal and urinary disorders
Oliguria 13 (36) 13 (30) 8 (21) 32 (27)
Skin and subcutaneous tissue disorders
Subcutaneous emphysema 1 (3) 5 (11) 6 (16) 12 (10)
Vascular disorders
Hypotension NOS 3 (8) 3 (7) 4 (11) 10 (8)
Respiratory, thoracic, and mediastinal
disorders
Atelectasis 3 (8) 13 (30) 11 (28) 27 (23)
Pleural effusion 2 (6) 2 (5) 6 (16) 10 (8)
Pneumothorax 4 (11) 7 (16) 6 (16) 17 (14)
Respiratory acidosis 2 (6) 5 (11) 4 (11) 11 (9)
*If a subject had the same adverse event 2 or more times, the adverse event was only counted once.There were no mortalities and no serious AEs. The most
common AEs were expected after surgical coarctation repair
(pain, agitation, and anemia). Despite the maximum esmolol
concentration of 20mg/mL, only 1 patient had irritation at the
site of intravenous administration. Because metabolic acido-
sis (28%) and hypokalemia (27%) are common after cardiac
surgery, in the absence of nonsurgical controls, it is beyond
the limits of this study to determine whether esmolol played
a role. There was no effect of dose range on the incidence of
AEs.
The results of this study demonstrate that esmolol
decreases SBP immediately after repair of CoA in infants
and children, with no significant untoward events. This
study is unique in the fact that it is perioperative and
multi-institutional (United States and Canada) and crosses
age groups (newborn to 6 years) and disciplines (surgeons,
anesthesiologists, and intensivists). The collaboration for
this study helped to lay the foundation and infrastructure
for current, ongoing, multi-institutional pediatric cardiac
trials.The Journal of ThoStudy Limitations
Because of concern over the risk of early postoperative bleed-
ing from the aortic suture line, the use of a placebo control
was believed to be unsafe. The dose range was limited by cur-
rent practice in this patient population. The wide age range
was chosen to enable an adequate study population. The in-
traoperative time period within 30 minutes of aortic cross-
clamp release was chosen to achieve the most uniform
patient condition. Thus most patients were still receiving in-
haled anesthetic, the vasodilating properties of which might
diminish the effect of esmolol. The combination of these fac-
tors is the most likely explanation for why the decrease in
SBP with esmolol was not statistically significant between
dose groups.
Furthermore, pharmacokinetic data analyses found that
steady-state esmolol blood levels were achieved 20 minutes
after the bolus was administered; however, primary efficacy
measures were determined only 5 minutes after the esmolol
bolus, perhaps underestimating the optimal effect of esmolol
on decreasing blood pressure.racic and Cardiovascular Surgery c Volume 136, Number 2 327
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CH
DConclusions
Esmolol safely and significantly decreases SBP immediately
after surgical repair of CoA in infants and children. However,
no difference was found between doses (125, 250, and 500
mg $ kg21 $min21). This study lays the foundation for deter-
mining the effect of higher doses of esmolol on blood pres-
sure from both an age-dependent and drug-combination
(eg, nitroprusside) approach.
We thank Cheng-Tao Chang, PhD, for his help with the statis-
tics.
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